Articles

Obefazimod: Abivax Ulcerative Colitis Drug Faces Efficacy vs. Safety Scrutiny

Abivax's obefazimod has demonstrated significant efficacy in ulcerative colitis trials, generating excitement for potential regulatory approval. However, recent reports of cancer cases necessitate a careful evaluation of its safety profile by investors and business development teams.

: Eli Lilly Leads Pharma R&D Rankings: Insights and Implications

Eli Lilly secured the top spot in a prominent pharma R&D performance ranking published May 19, 2026. This plan outlines the event, its implications for strategy and BD teams, and answers common questions.

Merck's ADC Success: Insights from Global Trial Results

This article delves into Merck's successful antibody-drug conjugates (ADCs) and their global trial results, highlighting key insights for investors and BD teams.

UCB's Bimzelx Triumphs Over AbbVie's Skyrizi in Psoriatic Arthritis

UCB's Bimzelx has shown superior efficacy compared to AbbVie's Skyrizi in treating psoriatic arthritis, marking a significant milestone in the competitive landscape. This article analyzes the implications for pharmaceutical business development teams.

Niowave's $75M Radiopharmaceutical Plant: Industry Implications

Niowave has initiated construction on a $75 million radiopharmaceutical plant in Michigan, marking a significant investment in Actinium-225 production. This development has far-reaching implications for the pharmaceutical industry and investment strategies.

Leadership Changes at FDA: Implications for Pharma

Recent leadership changes at the FDA signal a pivotal shift in drug regulation. This article outlines the implications for pharmaceutical businesses.

FDA Leadership Changes: Implications for the Pharmaceutical Industry

This article analyzes the recent leadership changes at the FDA and their potential impact on the pharmaceutical industry, focusing on business development and regulatory strategies.

How to Use openFDA and FAERS Data Without Misreading Safety Signals

This article provides insights on effectively using openFDA and FAERS data while avoiding common pitfalls in interpreting safety signals. It is essential for analysts and business development teams in the pharmaceutical industry.

2026 Orphan Drugs Report: Navigating Challenges Ahead

The 2026 Orphan Drugs Report highlights critical trends and challenges in the orphan drug landscape, offering insights for pharmaceutical stakeholders.

Tech Initiatives at Summa Health Post-General Catalyst Acquisition

This article discusses the technology initiatives at Summa Health following its acquisition by General Catalyst, highlighting key insights for B2B readers.

Revolution Medicines' Pancreatic Cancer Drug: Practice-Changing Results

Revolution Medicines has reported groundbreaking results for its pancreatic cancer drug, potentially transforming treatment protocols. This article explores the implications for the pharmaceutical industry.

Akeso and Summit Drug Shows Promise in Lung Cancer Trial

Akeso and Summit's recent lung cancer trial results indicate significant survival benefits. This article explores the implications for the pharmaceutical industry.

Ultra-Low Doses: A Game Changer for Cancer Treatment Access

Ultra-low doses of cancer treatments could significantly improve accessibility for patients in low-income regions. This article discusses recent developments and implications for the pharmaceutical industry.

RevMed's Triumph and Akeso's Caution: Insights from STAT+

RevMed receives accolades for its recent advancements while Akeso faces scrutiny. This article dissects the implications for the pharmaceutical industry.

14 New Weight Loss Drugs: Regulatory Updates and Implications

This article tracks the latest regulatory updates on 14 new weight loss drugs, focusing on implications for pharmaceutical teams and investors. Key insights on FDA processes included.

Biotech Stocks Facing FDA Decision in June 2026: Key Insights

This article analyzes biotech stocks awaiting FDA decisions in June 2026, highlighting investment implications and competitive impacts.

Commissioner's National Priority Voucher Pilot Program: Clinical Trials Insights

This article analyzes the CNPV Pilot Program's implications for clinical trials and investment strategies in the pharmaceutical sector.

Upcoming BIO 2026: Key Insights for B2B Readers

BIO 2026 is set to take place in San Diego from June 22-25, 2026. This event will showcase pivotal advancements in biotechnology and pharmaceutical sectors.

Get Ready for BIO 2026: Key Insights and What to Expect

The BIO 2026 event in San Diego promises to be a pivotal gathering for the biotech industry. Attendees can expect insights on emerging trends and key company developments.

Replimune's Third FDA Approval Attempt and Pfizer's China Deal

This article analyzes Replimune's third attempt for FDA approval and Pfizer's recent deal in China, highlighting implications for investors and pharma teams.